Markets Bet on Peace | Buffett Buys the Bottom | Novartis Joins the RNA Race

The world’s two largest economies just blinked at the same time, and traders cheered.

Global markets ripped higher Monday after Washington and Beijing said they’d reached a preliminary framework on key trade disputes, signaling a temporary ceasefire ahead of this week’s Trump–Xi summit.

Dow futures surged 250 points, S&P 500 futures gained 0.8%, and the Nasdaq leapt 1.2%, powered by risk-on rotation across Asia and Europe. The Chinese yuan strengthened, the Australian dollar followed, and gold sank nearly 2% as safe-havens bled. The 10-year Treasury yield pushed back above 4%... a quiet vote of confidence that maybe, just maybe, the worst is behind us.

Treasury Secretary Scott Bessent called the deal “a very successful framework”... promising tariff relief, renewed Chinese soybean imports, and a one-year pause on rare-earth export controls. 

The move would freeze the 100% tariffs set for November, removing one of the biggest geopolitical risk premiums haunting global supply chains.

Chipmakers led the charge premarket — Nvidia, Broadcom, and AMD up roughly 2% each — while traders positioned for a double catalyst: a potential Fed rate cut Wednesday and Big Tech’s earnings gauntlet from Microsoft, Alphabet, Meta, Apple, and Amazon.

Soybean futures jumped nearly 2% on the trade thaw. Oil and gold both retreated, unwinding last week’s sanction-driven bid.

The Setup: Relief or Reversal?

Markets are acting like they’ve seen this movie before… and this time it ends happily. Inflation is easing, central banks are turning dovish, and trade tensions appear to be cooling. But optimism has an expiration date.

The rally now hinges entirely on confirmation, not conversation. A handshake between Trump and Xi would validate the risk-on trade and likely ignite a year-end melt-up across cyclicals, industrials, and tech.

But if talks stall or headlines sour, the unwind will be brutal.

Investor Signal

This week’s playbook is simple but dangerous:

Right now, consensus is chasing comfort. Smart money knows comfort never lasts.

Every bull run starts as a relief rally,and ends when traders confuse hope for policy.
The question this week isn’t whether Trump and Xi can make peace. It’s whether markets can hold their nerve when the applause fades.

Wall Street’s big money is already moving — quietly building positions in a handful of stocks before the next rally.

Our analysts tracked the flows and found 10 companies leading the charge.

Some are household names. Others are under-the-radar innovators about to break out.

Together, they form the Post-Rate-Cut Playbook smart investors are following right now.

See Wall Street’s Top 10 Stocks for Fall — free before it moves behind the paywall >>

Rare earth stocks cracked Monday… not because tensions rose, but because they didn’t.

Critical Metals fell nearly 9% premarket, USA Rare Earth dropped 7%, and MP Materials slid over 5% after U.S. officials said Beijing will postpone new export controls as part of a broader trade deal expected at this week’s Trump–Xi summit.

For weeks, traders had bet that China might weaponize its dominance in rare earths, a sector it controls from mine to magnet. 

That fear bid prices up. The latest signals flipped the trade: Washington gets tariff relief; Beijing delays restrictions. Risk-off for scarcity.

Treasury Secretary Scott Bessent called it “a constructive step.” Translation: both sides blinked.

China still controls roughly 70% of global mining and nearly 90% of processing. By pausing instead of prohibiting, Beijing buys time, stabilizes sentiment, and looks cooperative… all while quietly stockpiling materials and tightening informal export routes.

For Washington, the delay is just as tactical. It sidesteps a fresh inflation spike, cools political heat heading into an election year, and keeps manufacturers from panic-pricing inputs. 

Behind the curtain, the U.S. is accelerating joint refining projects in Malaysia and Canada, an attempt to dilute China’s chemical chokehold without a public fight.

Behind the Handshake

This isn’t decoupling; it’s détente by necessity. The U.S. can mine rare earths, but China still refines them into power.
Every electric vehicle, wind turbine, and missile guidance system depends on that chemistry — and that’s where Beijing’s leverage endures.

A handshake in Washington may cool headlines, but the supply chain remains asymmetric. The pause is diplomacy disguised as progress.

Investor Signal

Monday’s sell-off is short-term relief, not long-term resolution.
U.S. miners just lost a scarcity premium, but the global equation hasn’t changed, supply is still fragile, and processing independence remains the real catalyst.

Watch: North American refining projects.
Ignore: The photo-op optimism.

The next durable rally in rare earth equities won’t be sparked by geopolitics — it’ll be when the West can finally make its own magnets.

Warren Buffett is back where most investors won’t go… into the smoke and steel of America’s industrial base.

Berkshire Hathaway’s $9.7 billion purchase of Occidental Petroleum’s chemical unit, OxyChem, marks a rare second act for Buffett in a sector that burned him once before.

His 2011 deal for Lubrizol never lived up to the legend. Fifteen years on, revenue barely up 20%, profits flat, and returns lagging the S&P 500 by miles.
But this time feels different.

Buffett’s buying when sentiment’s at its lowest — near the trough of the chemical cycle — paying roughly 12× projected 2025 pretax earnings. If pricing stabilizes, earnings could rebound sharply next year.

OxyChem’s portfolio … PVC, caustic soda, chlorine … ties directly to housing, autos, and the domestic energy build-out. 

That gives Berkshire leverage to the same forces fueling America’s industrial revival: data centers, pipelines, and onshoring plants.

The Pattern: Buying When the Dust Settles

This move fits Buffett’s oldest playbook…step into capital-intensive industries when others are walking out, collect steady cash flow, and wait for the turn.

OxyChem feeds the bones of the real economy…construction, packaging, and industrial materials. As rates ease and infrastructure dollars flow, volume should follow.

It’s also classic Berkshire positioning: tangible assets, recurring earnings, and the patience to let the cycle reset. Unlike Lubrizol’s specialty niche, OxyChem sits closer to the economic heartbeat, where scale matters more than story.

Investor Signal

Buffett’s timing says more than his words ever could.
He’s betting the industrial winter is ending, that the U.S. manufacturing flywheel is about to spin again.

If he’s right, OxyChem could become the next Alleghany, not the next Lubrizol.
For investors watching the tape, that logic points toward diversified chemical and building-material names positioned for the housing, infrastructure, and reshoring wave.

Follow Buffett’s cue: buy when the factories are quiet. Sell when the machines are loud.

George Gilder has identified 9 major tech convergences throughout history. Each created massive new wealth for the few who saw it coming.

The microchip. The internet. The iPhone. Qualcomm's wireless revolution.

Now he's tracking something he calls “Convergence X” - and he says a bombshell October 16th announcement is when it goes mainstream.

Three companies sit at the epicenter.

Get positioned before today’s bombshell announcement.

Corporate America is rewriting its headcount math… and this time, the answer isn’t more people.

From JPMorgan to Walmart, executives are testing a new formula: grow revenue, not payrolls.
The same output, or more, with fewer hands on deck.

JPMorgan’s CFO told investors the bank now has a “strong bias” against reflexive hiring. RTX, Goldman Sachs, and Intuit echoed the stance. Walmart plans to keep its workforce flat for the next three years even as revenue rises.

At Airbnb, Brian Chesky says AI can make the existing team “considerably more productive.”

The logic is ruthless but rational: if software can scale, salaries don’t have to.
Every open role now triggers a question, not a requisition.

At Intuit, that question became policy…no position is refilled without proof of need. The result? Headcount steady, revenue up 16%. The CFO calls it “a cure for corporate bloat.”

But cures can have side effects.
Meta just cut 600 AI division jobs to “reduce bureaucracy.” Target and Rivian trimmed staff citing “efficiency.”
The new discipline is spreading … and testing how lean corporate America can get before it starts cutting into bone.

The Macro Equation

This is the quiet shift shaping the next cycle: growth decoupled from jobs.
If it works, margins could hit highs not seen since the early 2000s.
If it fails, the next expansion could stall before it starts … thin benches, brittle cultures, and too few people to execute.

Flat headcounts across major employers mean slower wage growth, softer consumption, and potentially cooler inflation …  an outcome the Fed won’t fight.
But the same dynamic could sap demand just as policy turns supportive.

Investor Signal

Markets are rewarding discipline over dynamism.
Wall Street loves margins that rise without payroll bloat … especially in tech and finance … but every saved job is also a missing paycheck.

That means earnings may surprise to the upside, while GDP and sentiment lag behind.
For investors, that’s both the opportunity and the warning:

Buy efficiency; monitor humanity.
Because if this new corporate math holds, the next boom could feel strangely jobless.

Two generations, one economy … and they’re living different realities.

Across America, a generation that built wealth on stable jobs, cheap mortgages, and a relentless bull market is watching its children drift in an economy that no longer plays by the same rules.

Older Americans feel secure, yet uneasy. 

Their balance sheets are solid; their optimism is not. They see their children’s struggle as proof that the system that once rewarded effort now punishes entry.

Nearly 70% of respondents in a new WSJ–NORC poll said the American dream no longer holds true. Most older participants described their finances as comfortable … but doubted their children would do better.
What was once a path … job, house, savings, progress … now feels like nostalgia.

The Reversal Inside the Family

For young workers, headwinds come from every direction.

Entry-level hiring has slowed, recent graduates face 6.5% unemployment … the highest in a decade outside the pandemic … and housing costs have exploded nearly 50% since 2020.

Automation has turned recruiting into algorithms, leaving candidates unseen. Those who find work are paying record rent or living back home with parents who own their houses outright.

Multigenerational living, once a safety net, has become a default strategy. Parents who weathered recessions now subsidize their children’s adulthood … not because of failure, but because the math no longer works.

The Generational Reversal

The reversal runs deeper than income.
It’s a transfer of optimism. 

Parents who survived downturns now fear structural walls their kids can’t climb in housing, education, and work.

Consumption data shows the split: older homeowners are still spending; younger households are treading water. The imbalance is warping demand cycles, credit trends, and even national sentiment.

Economic confidence hasn’t collapsed … it’s been compartmentalized. Prosperity sits in the parent’s account; anxiety lives in the child’s future.

Investor Signal

The divide isn’t just social … it’s investable.

Homebuilders tied to traditional mid-market buyers face slower orders until affordability breaks. But those pivoting toward smaller, lower-cost models could lead the next upcycle once rates ease.

In the meantime, single-family rental REITs, multifamily operators, and home-improvement retailers are quietly winning … feeding the stay-put economy while household formation stalls.

The signal: the housing engine of long-term growth isn’t broken, it’s idling.
When affordability turns, the builders ready with entry-level inventory will move first.

Until then, the parents keep spending, the children keep waiting .. and the American dream remains under renovation.

The floodgates have opened.

Bitcoin and Ethereum ETFs are hitting record inflows — Wall Street’s finally all-in on crypto.

But while everyone’s chasing the big names, one undervalued altcoin is quietly rewriting the rules of finance.

It’s already processing billions… turning investors into their own banks… and outpacing Wall Street’s old money machine.

Now, with the Fed Pivot igniting a new bull run, this crypto is primed for liftoff.

See the altcoin that could leave Wall Street in the dust >>

© 2025 Boardwalk Flock LLC. All Rights Reserved. 2382 Camino Vida Roble, Suite I Carlsbad, CA 92011, United States. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Readers acknowledge that the authors are not engaging in the rendering of legal, financial, medical, or professional advice. The reader agrees that under no circumstances Boardwalk Flock, LLC is responsible for any losses, direct or indirect, which are incurred as a result of the use of the information contained within this, including, but not limited to, errors, omissions, or inaccuracies. Results may not be typical and may vary from person to person. Making money trading digital currencies takes time and hard work. There are inherent risks involved with investing, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk.

Novartis just placed one of the year’s boldest biotech wagers, a $12 billion all-cash takeover of Avidity Biosciences.

The Swiss pharma giant will pay $72 a share, a 46% premium, to secure Avidity’s pipeline of RNA-based therapeutics aimed at muscle and rare diseases.

For a company built on blockbuster chemistry, it’s a decisive leap back into biology’s newest language.

Avidity’s “antibody-oligonucleotide conjugates” marry antibodies and RNA strands, steering genetic payloads directly into muscle tissue … a precision play that could unlock entire families of new drugs.

The acquisition anchors Novartis’s broader U.S. push: fresh partnerships in cardiovascular and kidney research, a $23 billion R&D expansion, and a long-term growth target of 6% a year through 2029.

Pharma’s Return to Platform Science

For more than a decade, big pharma bought assets … single drugs that could patch aging portfolios.
Now it’s buying platforms, scientific engines that can manufacture multiple winners.

The Avidity move signals that shift. After mRNA’s breakout and CRISPR’s coming of age, RNA therapeutics are no longer fringe; they’re the next competitive frontier.

By owning its own RNA delivery system, Novartis positions itself beside Pfizer, Moderna, and Alnylam in the race to merge biologics with genetics.

The challenge now isn’t science, it’s speed. Can Novartis scale before the next generation of smaller RNA shops capture the upside?

Investor Signal

This deal doesn’t just validate one company… it re-prices an entire niche.

Expect sympathy momentum in names like Arrowhead (ARWR) and Ionis (IONS) as investors chase RNA delivery platforms over oncology one-offs.

The next wave of biotech M&A will be less about miracle cures and more about modular science … technologies that can be repeated, licensed, and scaled.

The message from Novartis is clear: the future isn’t one drug at a time. It’s one platform, infinite pipelines.

Markets are moving as if détente is destiny.
Every rally …  from semiconductors to soybeans …  now leans on the assumption that the Trump–Xi summit will end with more handshake than headline.

Easing inflation, dovish central banks, and a thaw in trade have given investors something rare this year: synchronized optimism.

But this calm is constructed. China’s pause on rare-earth restrictions and Washington’s tariff deferral are tactical, not structural. Both sides are buying time, not trust.

Behind the diplomacy sits the same rivalry — over inputs, data, and energy — that will define the next phase of global growth.

For now, markets are content to price peace.
But beneath the rally hums a quieter question:

If policy calm is the catalyst… what happens when the theater ends?